Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Sep 1, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called tranexamic acid to help reduce bleeding during and after surgery for patients with metastatic spinal tumors related to lung cancer. Massive blood loss can happen during these surgeries, leading to serious complications, so the researchers want to see if tranexamic acid can make a difference compared to patients who do not receive this medication.

To be eligible for this trial, participants must have a diagnosed metastatic tumor in the thoracolumbar spine (the lower part of the back) that affects only one section of the spine and are scheduled for separation surgery. However, patients with certain conditions, such as abnormal blood clotting or allergies to tranexamic acid, will not be included. Those who join the trial can expect to receive either the medication or standard care during their surgery, and the study will monitor their bleeding levels closely. This trial is currently recruiting participants of all genders aged between 18 and 80 years.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed as metastatic carcinoma of the thoracolumbar spine
• • solitary neoplasm involve only one segment of spine
• • patients underwent separation surgery
• Exclusion Criteria:
• • coagulation function was abnormal preoperatively
• • patients are allergic to tranexamic acid
• • neoplasm involve more than one segment of spine
• • patients with rich blood supply who need embolization